Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PF-08046033 in advanced solid tumors
NL-OMON61475Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of PF-08046033 in Nonhematologic neoplasms, sponsored by Pfizer. Primary endpoint: Primary endpoint(s). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PF-08046033
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON61475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61475.